These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17717874)

  • 21. Rimonabant: marketing authorization suspended... at last: withdrawal. Half-measures.
    Prescrire Int; 2009 Apr; 18(100):61. PubMed ID: 19585720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo.
    Prescrire Int; 2007 Dec; 16(92):250. PubMed ID: 18092422
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacotherapy for obesity--promise and uncertainty.
    Yanovski SZ
    N Engl J Med; 2005 Nov; 353(20):2187-9. PubMed ID: 16291989
    [No Abstract]   [Full Text] [Related]  

  • 24. [Selective cannabinoid receptor antagonists].
    Kreutz S; Korf HW; Schubert-Zsilavecz M
    Pharm Unserer Zeit; 2006; 35(6):512-20. PubMed ID: 17137082
    [No Abstract]   [Full Text] [Related]  

  • 25. [In diabetes cannabinoid antagonist kills two birds with one stone].
    MMW Fortschr Med; 2005 Sep; 147(35-36):10. PubMed ID: 16180564
    [No Abstract]   [Full Text] [Related]  

  • 26. [Endocannabinoid and endocannabinoid receptor antagonists].
    Heinzl S
    Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333
    [No Abstract]   [Full Text] [Related]  

  • 27. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
    Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179
    [No Abstract]   [Full Text] [Related]  

  • 28. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.
    Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV
    Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile.
    Cohen Y; Kolodziej A; Morningstar M
    Obesity (Silver Spring); 2024 Jul; 32(7):1235-1244. PubMed ID: 38887179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A new pill for metabolic syndrome. Successful control of lipids, kilos and cigarettes].
    Einecke D
    MMW Fortschr Med; 2004 Mar; 146(13):10-1. PubMed ID: 15219119
    [No Abstract]   [Full Text] [Related]  

  • 31. [Sleep disorders associated with treatment with rimonabant].
    Sempere AP; Giner-Bernabeu JC; Berenguer-Ruiz L; Selles-Galiana MF; Hernandez-Rubio L; Lezcano-Rodas M
    Rev Neurol; 2008 Oct 16-31; 47(8):446. PubMed ID: 18937208
    [No Abstract]   [Full Text] [Related]  

  • 32. Withdrawal of Rimonabant--walking the tightrope of 21st century pharmaceutical regulation?
    Taylor D
    Curr Drug Saf; 2009 Jan; 4(1):2-4. PubMed ID: 19256104
    [No Abstract]   [Full Text] [Related]  

  • 33. [2008: the end of rimonabant's story].
    Paris M
    Ann Pharm Fr; 2009 May; 67(3):167-8. PubMed ID: 19446664
    [No Abstract]   [Full Text] [Related]  

  • 34. Rimonabant: new drug. Obesity: loss of a few kilos, many questions.
    Prescrire Int; 2006 Aug; 15(84):123-6. PubMed ID: 16977739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A drug for therapy of obesity: really only life style? (interview by Dirk Einecke)].
    Wirth A
    MMW Fortschr Med; 2006 Nov; 148(46):17. PubMed ID: 17615781
    [No Abstract]   [Full Text] [Related]  

  • 36. Depression and weight loss: opposite outcome for surgery and rimonabant?
    Chaput JP; Tremblay A
    Obes Rev; 2008 Sep; 9(5):504-7. PubMed ID: 18643944
    [No Abstract]   [Full Text] [Related]  

  • 37. Rimonabant in obese patients with type 2 diabetes.
    Randall MD; Kendall DA; Bennett AJ; O'Sullivan SE
    Lancet; 2007 Feb; 369(9561):555. PubMed ID: 17307094
    [No Abstract]   [Full Text] [Related]  

  • 38. Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction.
    Gadde KM
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):549-56. PubMed ID: 16503875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans.
    Bergholm R; Sevastianova K; Santos A; Kotronen A; Urjansson M; Hakkarainen A; Lundbom J; Tiikkainen M; Rissanen A; Lundbom N; Yki-Järvinen H
    Int J Obes (Lond); 2013 May; 37(5):699-703. PubMed ID: 22828945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.